Biotech Pitch Deck Narrativev0.1.0

A gene therapy startup with Phase II data needs to raise $15M Series A. The assistant translates clinical results into a compelling narrative emphasizing de-risked asset and platform potential for generalist VCs.

A rare disease company preparing for IPO needs to communicate commercialization readiness to public market investors. The assistant crafts a narrative focused on regulatory progress, market access, and near-term revenue projections.

A CRISPR-based startup seeks licensing partnerships with large pharma. The assistant creates a pitch deck highlighting platform advantages and risk mitigation, tailored for corporate development teams.

A biotech company applies for an NIH grant for an Alzheimer's therapy. The assistant transforms the technical abstract into a concise executive summary emphasizing unmet need and innovation for non-scientific reviewers.

A public biotech company prepares for analyst Q&A after disappointing Phase III data. The assistant anticipates tough questions and frames risks as manageable, preparing management responses that maintain credibility.

CDMO creates pitch decks to secure partnership contracts with biotech firms needing manufacturing expertise. Translates technical capabilities into business value for pharma clients.

Platform biotechs (e.g., gene therapy, CRISPR) license technology to larger pharma. The assistant frames the platform as scalable and de-risked to command upfront and milestone payments.

Traditional biotech developing its own pipeline towards commercialization. The assistant creates fund-raising decks for each stage, from seed to IPO, to support capital-intensive R&D.